Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical improvement | clinical worsening | deaths | PCR-negative conversion |
| Immunosuppressants drugs | 24 | 1.17 [1.00; 1.38], 5 RCTs, I2=0%
low degree of certainty | 0.78 [0.53; 1.14], 4 RCTs, I2=36%
inconclusive result | 1.08 [0.77; 1.52], 6 RCTs, I2=0%
inconclusive result | - | |
| Immunostimulants drugs | 23 | 1.16 [0.78; 1.74], 4 RCTs, I2=52%
inconclusive result | 0.63 [0.08; 4.94], 2 RCTs, I2=53%
inconclusive result | 1.10 [0.93; 1.29], 8 RCTs, I2=0%
inconclusive result | 6.33 [1.54; 26.00], 1 RCT, I2=0%
unassessable degree of certainty | |
| corticosteroids | 13 | 1.16 [0.84; 1.60], 2 RCTs, I2=0%
inconclusive result | 0.66 [0.43; 1.02], 1 RCT, I2=0%
inconclusive result | 0.81 [0.65; 0.99], 7 RCTs, I2=59% demonstrated
low degree of certainty | - | |
| anti-inflammatory therapies | 3 | OBS 12.75 [1.61; 100.79], 1 study, I2=0%
unassessable degree of certainty | OBS 0.43 [0.02; 8.34], 2 studies, I2=88%
inconclusive result | OBS 0.41 [0.19; 0.89], 1 study, I2=0%
very low degree of certainty | - | |
| acalabrutinib | 2 | - | - | - | - | |
| A EFFACER anticorps | 0 | - | - | - | - | |
| Apilimod | 0 | - | - | - | - | |
| imatinib | 0 | - | - | - | - | |
| leflunomide | 0 | - | - | - | - | |
| pirfenidone | 0 | - | - | - | - | |
| Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
| sargramostim | 0 | - | - | - | - | |
| thymosin | 0 | - | - | - | - | |
